Incidence of systemic inflammatory response syndrome and patient outcome following transcatheter edge-to-edge mitral valve repair.
Inflammation
Mitral valve regurgitation
SIRS
Transcatheter edge-to-edge mitral valve repair
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
23 Oct 2023
23 Oct 2023
Historique:
received:
23
06
2023
accepted:
21
09
2023
medline:
23
10
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
aheadofprint
Résumé
Systemic inflammatory response syndrome (SIRS) is a common finding after cardiovascular interventions. Data on the incidence of SIRS and its impact on outcome in patients undergoing transcatheter edge-to-edge mitral valve repair (MV-TEER) for mitral regurgitation (MR) is lacking. From January 2013 to December 2020, 373 patients with moderate or severe MR undergoing MV-TEER were included. SIRS was defined as at least two of the following criteria within 48 h after the procedure: leucocyte count > 12.0 or < 4.0 × 10 SIRS was observed in 49.6% (185/373) of patients. Patients who developed SIRS presented more frequently with NYHA III/IV at baseline [SIRS: 82.4% (149/185) vs. no SIRS: 79.0% (147/188); p = 0.029]. Patients who developed SIRS spent more days on ICU (p < 0.001) and overall length of stay was longer (p < 0.001). Relevant residual MR, defined as MR ≥ III in-hospital, was present more often in patients who developed SIRS [SIRS: 11.3% (20/177) vs. no SIRS: 3.93% (7/178), p = 0.036]. At 3 years, all-cause mortality in the entire population was 33.5% (125/373) with an increased all-cause mortality in patients with SIRS compared to patients without SIRS (HR 1.49, [CI 95% 1.04, 2.13]; p = 0.0264). In the multivariate analysis development of SIRS (HR 1.479 [CI 95% 1.016, 2.154]; p = 0.041) was identified as predictor for 3-years all-cause mortality. SIRS is a common finding after MV-TEER occurring in approximately half of patients. SIRS after MV-TEER was associated with a longer in-hospital stay. In addition, we observed an increased 3-years all-cause mortality in patients with SIRS.
Identifiants
pubmed: 37870627
doi: 10.1007/s00392-023-02316-y
pii: 10.1007/s00392-023-02316-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP III, Gentile F et al (2021) 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 143(5):e72–e227. https://doi.org/10.1161/cir.0000000000000923
doi: 10.1161/cir.0000000000000923
pubmed: 33332150
Nita N, Schneider L, Dahme T, Markovic S, Keßler M, Rottbauer W et al (2022) Trends in transcatheter edge-to-edge mitral valve repair over a decade: data from the MiTra ULM Registry. Front Cardiovasc Med 9:850356. https://doi.org/10.3389/fcvm.2022.850356
doi: 10.3389/fcvm.2022.850356
pubmed: 35350535
pmcid: 8957866
Diegeler A, Doll N, Rauch T, Haberer D, Walther T, Falk V et al (2000) Humoral immune response during coronary artery bypass grafting: a comparison of limited approach, “off-pump” technique, and conventional cardiopulmonary bypass. Circulation 102(19 Suppl 3):Iii95–Iii100. https://doi.org/10.1161/01.cir.102.suppl_3.iii-95
doi: 10.1161/01.cir.102.suppl_3.iii-95
pubmed: 11082370
Hirai S (2003) Systemic inflammatory response syndrome after cardiac surgery under cardiopulmonary bypass. Ann Thorac Cardiovasc Surg 9(6):365–370
pubmed: 15003097
Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA et al (2005) Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 165(14):1643–1650. https://doi.org/10.1001/archinte.165.14.1643
doi: 10.1001/archinte.165.14.1643
pubmed: 16043684
Paparella D, Yau TM, Young E (2002) Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 21(2):232–244. https://doi.org/10.1016/s1010-7940(01)01099-5
doi: 10.1016/s1010-7940(01)01099-5
pubmed: 11825729
Squiccimarro E, Labriola C, Malvindi PG, Margari V, Guida P, Visicchio G et al (2019) Prevalence and clinical impact of systemic inflammatory reaction after cardiac surgery. J Cardiothorac Vasc Anesth 33(6):1682–1690. https://doi.org/10.1053/j.jvca.2019.01.043
doi: 10.1053/j.jvca.2019.01.043
pubmed: 30772177
Sinning JM, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R et al (2012) Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J 33(12):1459–1468. https://doi.org/10.1093/eurheartj/ehs002
doi: 10.1093/eurheartj/ehs002
pubmed: 22285582
Schwietz T, Behjati S, Gafoor S, Seeger F, Doss M, Sievert H et al (2015) Occurrence and prognostic impact of systemic inflammatory response syndrome in transfemoral and transapical aortic valve implantation with balloon- and self-expandable valves. EuroIntervention 10(12):1468–1473. https://doi.org/10.4244/EIJY14M06_05
doi: 10.4244/EIJY14M06_05
pubmed: 24970670
Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P et al (2005) Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol 46(11):2134–2140. https://doi.org/10.1016/j.jacc.2005.07.065
doi: 10.1016/j.jacc.2005.07.065
pubmed: 16325053
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1–39. https://doi.org/10.1016/j.echo.2014.10.003 . (e14)
doi: 10.1016/j.echo.2014.10.003
pubmed: 25559473
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29(4):530–538. https://doi.org/10.1007/s00134-003-1662-x
doi: 10.1007/s00134-003-1662-x
pubmed: 12664219
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228. https://doi.org/10.1007/s00134-012-2769-8
doi: 10.1007/s00134-012-2769-8
pubmed: 23361625
pmcid: 7095153
Stone GW, Adams DH, Abraham WT, Kappetein AP, Généreux P, Vranckx P et al (2015) Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: a consensus document from the Mitral Valve Academic Research Consortium. Eur Heart J 36(29):1878–1891. https://doi.org/10.1093/eurheartj/ehv333
doi: 10.1093/eurheartj/ehv333
pubmed: 26170468
Tibshirani R (1997) The lasso method for variable selection in the Cox model. Stat Med 16(4):385–395. https://doi.org/10.1002/(sici)1097-0258(19970228)16:4%3c385::aid-sim380%3e3.0.co;2-3
doi: 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3
pubmed: 9044528
Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T et al (1996) Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 61(6):1714–1720. https://doi.org/10.1016/0003-4975(96)00055-0
doi: 10.1016/0003-4975(96)00055-0
pubmed: 8651772
Sablotzki A, Friedrich I, Mühling J, Dehne MG, Spillner J, Silber RE et al (2002) The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions. Perfusion 17(2):103–109. https://doi.org/10.1177/026765910201700206
doi: 10.1177/026765910201700206
pubmed: 11958300
Fransen E, Maessen J, Dentener M, Senden N, Geskes G, Buurman W (1998) Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 113(5):1290–1295. https://doi.org/10.1378/chest.113.5.1290
doi: 10.1378/chest.113.5.1290
pubmed: 9596308
Franke A, Lante W, Fackeldey V, Becker HP, Kurig E, Zöller LG et al (2005) Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? Eur J Cardiothorac Surg 28(4):569–575. https://doi.org/10.1016/j.ejcts.2005.07.007
doi: 10.1016/j.ejcts.2005.07.007
pubmed: 16135408
Kalinskaya A, Dukhin O, Lebedeva A, Maryukhnich E, Rusakovich G, Vorobyeva D et al (2022) Circulating cytokines in myocardial infarction are associated with coronary blood flow. Front Immunol 13:837642. https://doi.org/10.3389/fimmu.2022.837642
doi: 10.3389/fimmu.2022.837642
pubmed: 35242141
pmcid: 8886043
Lindman BR, Goldstein JS, Nassif ME, Zajarias A, Novak E, Tibrewala A et al (2015) Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement. Heart 101(7):537–545. https://doi.org/10.1136/heartjnl-2014-307057
doi: 10.1136/heartjnl-2014-307057
pubmed: 25605654
Izbicki G, Rudensky B, Na’amad M, Hershko C, Huerta M, Hersch M (2004) Transfusion-related leukocytosis in critically ill patients. Crit Care Med 32(2):439–442. https://doi.org/10.1097/01.Ccm.0000104951.94820.A9
doi: 10.1097/01.Ccm.0000104951.94820.A9
pubmed: 14758161
Xu K, Xie S, Huang Y, Zhou T, Liu M, Zhu P et al (2020) Cell-type transcriptome atlas of human aortic valves reveal cell heterogeneity and endothelial to mesenchymal transition involved in calcific aortic valve disease. Arterioscler Thromb Vasc Biol 40(12):2910–2921. https://doi.org/10.1161/atvbaha.120.314789
doi: 10.1161/atvbaha.120.314789
pubmed: 33086873
Ma H, Killaars AR, DelRio FW, Yang C, Anseth KS (2017) Myofibroblastic activation of valvular interstitial cells is modulated by spatial variations in matrix elasticity and its organization. Biomaterials 131:131–144. https://doi.org/10.1016/j.biomaterials.2017.03.040
doi: 10.1016/j.biomaterials.2017.03.040
pubmed: 28390245
pmcid: 5452973
Baum J, Duffy HS (2011) Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol 57(4):376–379. https://doi.org/10.1097/FJC.0b013e3182116e39
doi: 10.1097/FJC.0b013e3182116e39
pubmed: 21297493
pmcid: 3077448
Serrano-López J, Martín-Antonio B (2021) Inflammaging, an imbalanced immune response that needs to be restored for cancer prevention and treatment in the elderly. Cells. https://doi.org/10.3390/cells10102562
doi: 10.3390/cells10102562
pubmed: 34685542
pmcid: 8533838
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194–1217. https://doi.org/10.1016/j.cell.2013.05.039
doi: 10.1016/j.cell.2013.05.039
pubmed: 23746838
pmcid: 3836174
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E et al (2000) Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244–254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x
doi: 10.1111/j.1749-6632.2000.tb06651.x
pubmed: 10911963
Barcena ML, Aslam M, Pozdniakova S, Norman K, Ladilov Y (2022) Cardiovascular inflammaging: mechanisms and translational aspects. Cells. https://doi.org/10.3390/cells11061010
doi: 10.3390/cells11061010
pubmed: 35326461
pmcid: 8946971
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A (2018) Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 14(10):576–590. https://doi.org/10.1038/s41574-018-0059-4
doi: 10.1038/s41574-018-0059-4
pubmed: 30046148
Khansari N, Shakiba Y, Mahmoudi M (2009) Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov 3(1):73–80. https://doi.org/10.2174/187221309787158371
doi: 10.2174/187221309787158371
pubmed: 19149749
Franceschi C, Campisi J (2014) Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 69(Suppl 1):S4-9. https://doi.org/10.1093/gerona/glu057
doi: 10.1093/gerona/glu057
pubmed: 24833586
Jobs A, Grund S, de Waha-Thiele S, Ledwoch J, Sievert H, Rassaf T et al (2021) Deep sedation versus general anaesthesia for transcatheter mitral valve repair: an individual patient data meta-analysis of observational studies. EuroIntervention 16(16):1359–1365. https://doi.org/10.4244/eij-d-20-00607
doi: 10.4244/eij-d-20-00607
pubmed: 33046436
pmcid: 9724987
Jentzer JC, Lawler PR, van Diepen S, Henry TD, Menon V, Baran DA et al (2020) Systemic inflammatory response syndrome is associated with increased mortality across the spectrum of shock severity in cardiac intensive care patients. Circ Cardiovasc Qual Outcomes 13(12):e006956. https://doi.org/10.1161/circoutcomes.120.006956
doi: 10.1161/circoutcomes.120.006956
pubmed: 33280435
Cuinet J, Garbagnati A, Rusca M, Yerly P, Schneider AG, Kirsch M et al (2020) Cardiogenic shock elicits acute inflammation, delayed eosinophilia, and depletion of immune cells in most severe cases. Sci Rep 10(1):7639. https://doi.org/10.1038/s41598-020-64702-0
doi: 10.1038/s41598-020-64702-0
pubmed: 32377009
pmcid: 7203157
Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380(18):1695–1705. https://doi.org/10.1056/NEJMoa1814052
doi: 10.1056/NEJMoa1814052
pubmed: 30883058
Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D et al (2019) Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380(18):1706–1715. https://doi.org/10.1056/NEJMoa1816885
doi: 10.1056/NEJMoa1816885
pubmed: 30883053
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379(24):2307–2318. https://doi.org/10.1056/NEJMoa1806640
doi: 10.1056/NEJMoa1806640
pubmed: 30280640